Biocellvia has developed expertise in compound validation assay based on digital imaging analysis. Our technology allows us to measure the level of compound efficacy in a fully quantitative manner. Our automated analysis uses Artificial Intelligence to provide a more accurate, sensitive, reliable (100% reproducibility), and fully observer-independent technology than any other market technology.

As Proof of Concept, Biocellvia had the opportunity to collaborate with Boehringer Ingelheim to correlate and validate our IPF assay directly with conventional methods such as « Ashcroft scoring » and published this data in PLOS ONE.

“Quantification of pulmonary fibrosis in a bleomycin mouse model using automated histological image analysis” http://www.biocellvia.com/2017/02/14/biocellvia-publication-quantification-pulmonary-fibrosis/

Biocellvia’s assay supports solid, evidence-based decision-making on your drug compound based on robust data and accelerates your preclinical development; a conventional study (250 slides) only takes a few hours.
Our current validation assays portfolio :
• IPF, idiopathic pulmonary fibrosis: the new validated reference in pulmonary fibrosis evaluation
• COPD, chronic obstructive pulmonary disease: Emphysema: an innovative multi-parametric analysis
• COPD, chronic obstructive pulmonary disease: Small airway remodeling: a unique, comprehensive automated quantitative tool, peribronchial collagen included.
• NASH/NAFLD: Fibrosis, steatosis, ballooning inflammation quantification
• PAH, pulmonary arterial Hypertension.
• Kidney Fibrosis